C. Greilsamer

Patient Preference Between Cabazitaxel and Docetaxel for First-line Chemotherapy in Metastatic Castration-resistant Prostate Cancer: The CABADOC Trial.

S. Culine, G. Gravis, F. Joly, 2021, European urology.

Baseline tumour size is an independent prognostic factor for overall survival in PD-L1 ≥ 50% non-small cell lung cancer patients treated with first-line pembrolizumab

J. Bennouna, E. Frampas, T. Goronflot, 2021, Cancer Immunology, Immunotherapy.

CHEOPS trial: a GINECO group randomized phase II assessing addition of a non-steroidal aromatase inhibitor to oral vinorelbine in pre-treated metastatic breast cancer patients

A. Arnaud, T. Bachelot, R. Largillier, 2023, Breast Cancer.

Prognostic score for synchronous metastatic rectal cancer: A real-world study.

A. Lièvre, R. Guimbaud, O. Bouché, 2023, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

304P ESR1 mutations and outcomes in BRCA1/2 or PALB2 germline mutation carriers receiving first line aromatase inhibitor + palbociclib (AI+P) for metastatic breast cancer (MBC) in the PADA-1 trial

J. Lemonnier, F. Bidard, M. Mouret-Reynier, 2020 .